Tenax Therap

Q3 FY2026 EarningsQ3 FY26 results beat consensus on both bottom-line metrics and liquidity, with a GAAP EPS of -$0.31 vs. -$0.36 expected. Net loss was $16.7M, notably narrower than the $19.0M consensus, primarily due to higher interest income and lower SG&A expenses. While the Phase 3 LEVEL trial failed its primary endpoint, a successful enrichment strategy for LEVEL-2 and a granted FDA Type C meeting provide a structured path forward. Cash reserves of $113.7M extend the runway through FY28, significantly exceeding typical biotech burn expectations.